XML 36 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8
Intangible Assets
 6 Months Ended
Jun. 30, 2014
Goodwill And Intangible Assets Disclosure [Abstract]  
Intangible Assets

NOTE 6—INTANGIBLE ASSETS

Intangible assets for in-process research and development (“IPR&D”) consist of two clinical product candidates from our acquisition of Ceregene. IPR&D is an intangible asset classified as indefinite-lived until the completion or abandonment of the associated research and development effort, and will be amortized over an estimated useful life to be determined at the date the project is completed.

A summary of these assets and estimated fair values are as follows (in thousands):

 

     As of
June 30, 2014		      As of
December 31, 2013		  

CERE-110 for the treatment of Alzheimer’s disease

    $ 1,640       $ 1,640   

CERE-120 for the treatment of Parkinson’s disease

      230         230   
  

 

 

     

 

 

  

Total identifiable intangible assets

    $ 1,870       $ 1,870   
  

 

 

     

 

 

  

The excess of the consideration transferred over the fair values assigned to the assets acquired and liabilities assumed, which is also known as goodwill, was $1.6 million. There was no change in goodwill for the six months ended June 30, 2014.